REGN peer analysis
Regeneron (REGN) against its competitors: price, today's move, 1-year return and market value side by side.
REGN and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| AMGN Amgen | $461.50 | 0.27% | 43.78% | $248.97B |
| AZN AstraZeneca | $185.92 | -0.50% | 14.74% | $289.79B |
| BIIB Biogen | $248.35 | 1.81% | 61.63% | $36.06B |
| EYPT EyePoint | $0.36 | 0.31% | -96.96% | $30.68M |
| GILD Gilead | $166.49 | -0.64% | 36.63% | $207.84B |
| GMAB Genmab | $53.89 | 2.17% | 82.94% | $32.43B |
| NVS Novartis | $162.50 | 0.36% | 29.53% | $305.82B |
| OCUL Ocular Therapeutix | $6.65 | 3.45% | -38.48% | $1.41B |
| REGN Regeneron | $900.00 | -0.32% | 40.51% | $93.40B |
- REGN's peers: AMGN (Amgen), AZN (AstraZeneca), BIIB (Biogen), EYPT (EyePoint), GILD (Gilead), GMAB (Genmab), NVS (Novartis), OCUL (Ocular Therapeutix).
Updated 2026-11-07 11:56 UTC